Trinity Biotech Invests in Rapid Sepsis Testing Innovation
Company Announcements

Trinity Biotech Invests in Rapid Sepsis Testing Innovation

Trinity Biotech (TRIB) has released an update.

Trinity Biotech has made a strategic investment of $2.5 million to acquire a 12.5% equity stake in Novus Diagnostics, a company developing rapid sepsis testing technology. This partnership is expected to expedite the development and market introduction of Novus’ innovative point-of-care diagnostic solutions, potentially transforming sepsis management and saving lives. The investment highlights Trinity Biotech’s commitment to advancing critical diagnostic tools and leveraging its expertise in manufacturing and commercialization.

For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTrinity Biotech Secures Nasdaq Compliance, Eyes Growth
TheFlyTrinity Biotech regains compliance with Nasdaq listing requirements
TipRanks Auto-Generated NewsdeskTrinity Biotech Acquires EpiCapture to Enter Oncology Market
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App